AntriaBio, Inc. Appoints Dr. Robert B. Bhisitkul to Its Scientific Advisory Board
October 04, 2017 at 05:30 pm IST
AntriaBio, Inc. announced the appointment of Dr. Robert B. Bhisitkul, M.D., Ph.D. to its Scientific Advisory Board. The addition of Dr. Bhisitkul to the Scientific Advisory Board follows the company’s recent in-licensing of an oral plasma kallikrein inhibitor (PKI) portfolio announced on August 7th. As such, AntriaBio is bolstering its leadership team and allocating resources to develop treatments for kallikrein-mediated diseases, diabetic macular edema (DME) and hereditary angioedema (HAE). Dr. Bhisitkul is a Professor of Clinical Ophthalmology and retinal specialist at the University of California, San Francisco School of Medicine’s Department of Ophthalmology.